Newsroom

Strive to Deliver Breakthroughs

  1. May 23, 2024

    Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

    Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...

    View more
  2. March 28, 2024

    Harbour BioMed Reports Full Year 2023 Financial Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...

    View more
  3. January 24, 2024

    Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

    Cambridge, MA, Rotterdam, NL, Suzhou, CN   Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...

    View more
  4. January 19, 2024

    Harbour BioMed Announces Positive Profit Alert

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...

    View more
  5. December 15, 2023

    Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

    Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...

    View more
  6. August 28, 2023

    Harbour BioMed Announces 2023 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...

    View more
  7. August 28, 2023

    Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023   Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...

    View more
  8. August 08, 2023

    Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...

    View more
  9. July 13, 2023

    Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  10. June 29, 2023

    Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more